Exploring the latest advances in firstline treatment of ES-SCLC: Translating the data to clinical practice



Disclaimer

- Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions
- The presenting faculty have been advised by USF Health and touchIME to ensure that they disclose any such references made to unlabelled or unapproved use
- No endorsement by USF Health and touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in USF Health and touchIME activities
- USF Health and touchIME accept no responsibility for errors or omissions







Dr Marina Garassino

University of Chicago, Chicago, IL, USA **Dr Luis Paz-Ares**

Hospital Universitario 12 de Octubre, Complutense University and Ciberonc, Madrid, Spain Dr Martin J Edelman

Fox Chase Cancer Center, Philadelphia, PA, USA





Advances in the first-line treatment of ES-SCLC: Where are we now?

Exploring safety with immunotherapy combinations: How can we mitigate side effects?

Emerging therapies for ES-SCLC: What is on the horizon?



ES-SCLC, extensive stage small cell lung cancer.

Advances in the first-line treatment of ES-SCLC: Where are we now?

Dr Marina Garassino

University of Chicago, Chicago, IL, USA





Approval status in first-line ES-SCLC






PD-L1 inhibitors **durvalumab** and **atezolizumab** are approved by the EMA,^{1,2} FDA^{3,4} and PMDA^{5,6} for the first-line treatment of ES-SCLC in combination with platinum-based chemotherapy

0

PD-1 inhibitors **pembrolizumab** and **nivolumab** were used in second- or later-line and assessed in clinical trials for first-line treatment of ES-SCLC,^{7,8} but they are no longer approved in any line of treatment

EMA, European Medicines Agency; ES-SCLC, extensive stage small cell lung cancer; FDA, US Food and Drug Administration; OS, overall survival; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; PI, prescribing information; PMDA, Pharmaceuticals and Medical Devices Agency; SmPC, summary of product characteristics. 1. EMA. Durvalumab SmPC. Available at <u>www.ema.europa.eu/en/medicines</u> (accessed 27 July 2022); 2. EMA. Atezolizumab SmPC. Available at: <u>www.ema.europa.eu/en/medicines</u> (accessed 27 July 2022); 3. FDA. Durvalumab PI. Available at: <u>www.accessdata.fda.gov/scripts/cder/daf/index.cfm</u> (accessed 27 July 2022); 4. FDA. Atezolizumab PI. Available at: <u>www.accessdata.fda.gov/scripts/cder/daf/index.cfm</u> (accessed 27 July 2022); 5. PMDA. Durvalumab Review Report. Available at: <u>https://www.pmda.go.jp/files/000243599.pdf</u> (accessed 22 June 2022); 6. PMDA. Atezolizumab Review Report. Available at: <u>https://www.pmda.go.jp/files/000235287.pdf</u> (accessed 22 June 2022); 7. Rudin CM, et al. *J Clin Oncol.* 2020;38:2369–79; 8. Leal T, et al. *J Clin Oncol.* 2020;38(Suppl. 15):9000.



Durvalumab + tremelimumab + EP* n=268



Primary endpoint: OS

Updated analysis: 25-month follow-up²

	Durvalumab + EP	EP alone	Durvalumab + tremelimumab + EP
Median OS, months	12.9	10.5	10.4
	Durvalumab + EP vs EP alone HR 0.75 (95% Cl 0.62–0.91)		No OS advantage compared with EP alone

*Investigator's choice of either carboplatin or cisplatin.

Cl, confidence interval; EP, etoposide-platinum; ES-SCLC, extensive stage small cell lung cancer; HR, hazard ratio; OS, overall survival; R, randomized. 1. Al-Salama ZT. *Target Oncol*. 2021;16:857–64; 2. Goldman JW, et al. *Lancet Oncol*. 2021;22:51–65.









Primary endpoints: OS, PFS

Updated analysis: 23-month follow-up

	Atezolizumab + EC	Placebo + EC	
Median OS, months	12.3	10.3	HR 0.76 (95% CI 0.60–0.95)
Median PFS, months	5.2	4.3	HR 0.77 (95% CI 0.62–0.96)

CI, confidence interval; EC, etoposide carboplatin; ES-SCLC, extensive stage small cell lung cancer; HR, hazard ratio; OS, overall survival; PFS, progression-free survival; R, randomized. 1. Liu SV, et al. *J Clin Oncol.* 2021;39:619–30.



 Exploring safety with immunotherapy combinations: How can we mitigate side effects?

Dr Marina Garassino

University of Chicago, Chicago, IL, USA





Overview of potential irAEs

Common toxicities

Fatigue

Infusion-related reactions

Gastrointestinal: nausea, diarrhoea, colitis, hepatitis

Skin: rash, pruritus

Musculoskeletal: arthralgia, myalgia

Ophthalmological: dry eye, uveitis

Endocrine: hypo-/hyperthyroidism

Pulmonary: pneumonitis

Renal: tubulointerstitial nephritis, AKI



Skin: pemphigus, pemphigoid, lichenoid rash, SJS/TEN

Endocrine: hypophysitis

Neurological: myasthenia gravis, Guillain-Barré syndrome

Haematological: thrombocytopenia, haemolytic anaemia

Cardiovascular: myocarditis

Musculoskeletal: myositis



AKI, acute kidney injury; irAE, immune-related adverse event; SJS/TEN, Stevens–Johnson syndrome/toxic epidermal necrolysis. Brahmer JR, et al. *J Immunother Cancer*. 2021;9:e002435.

irAEs with immunotherapies in ES-SCLC

Atezolizumab + EC¹



irAEs occurred in 40% of patients who received atezolizumab + CT

Most common irAEs




 Grade ≥3 irAEs included: rash (2%), IRRs (2%), hepatitis (1.5%), colitis (1%), pneumonitis (<1%), pancreatitis (<1%), rhabdomyolysis (<1%), nephritis (<1%), Guillain–Barré syndrome (<1%)

Durvalumab + EP^{2,3}



irAEs occurred in 20% of patients who received durvalumab + CT



 Grade ≥3 irAEs included: hepatic events (2%), type 1 diabetes mellitus (2%), pneumonitis (1%), diarrhoea/colitis (<1%) and pancreatic events (<1%)

CT, chemotherapy; EC, etoposide-carboplatin; EP, etoposide-platinum ;ES-SCLC, extensive stage small cell lung cancer; irAE; immune-related adverse event; IRR, infusion-related reactions.

1. Horn L, et al. N Engl J Med. 2018;379:2220-29; 2. Paz-Ares L, et al. Lancet. 2019;394:1929-39; 3. Hou W, et al. Front Oncol. 2021;11:604227.



Emerging therapies for ES-SCLC: What is on the horizon?

Dr Marina Garassino

University of Chicago, Chicago, IL, USA





Phase III clinical trials with ICIs in the first-line setting

Trial	Regimen	Status	Est. completion	Initial results
SKYSCRAPER-02 ¹ (NCT04256421)	Atezolizumab (anti-PD-L1) + EC + tiragolumab (anti-TIGIT)	Active, not recruiting	December 2022	 Median follow up: 13.9 months No PFS/OS benefit with the addition of tiragolumab Study ongoing until final OS analysis
ASTRUM-005 ² (NCT04063163)	Serplulimab (anti-PD-1) + EC	Recruiting	December 2022	 mOS: serplulimab 15.4 months vs placebo 10.9 months; HR 0.63, 95% CI 0.49–0.82; P<0.001 mPFS: serplulimab 5.8 months vs placebo 4.3 months; HR 0.47, 95% CI 0.38–0.59; P<0.001
CAPSTONE-1 ³ (NCT03711305)	Adebrelimab (anti-PD-L1) + EC	Active, not recruiting	October 2022	 Median follow up: 13.5 months mOS: adebrelimab 15.3 months vs placebo 12.8 months; HR 0.72, 95% CI 0.58–0.90; P=0.0017

CI, confidence interval; EC, etoposide-carboplatin; HR, hazard ratio; ICI, immune checkpoint inhibitor; mOS, median overall survival; mPFS, median progression-free survival; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; TIGIT, T cell immunoreceptor with immunoglobulin and ITIM domain. 1. Rudin CM, et al. *J Clin Oncol*. 2022;40:LBA8507; 2. Cheng Y, et al. *J Clin Oncol*. 2022;40:8505-8505; 3. Wang J, et al. *Lancet Oncol*. 2022;3:739-47.



Lack of biomarkers to predict response to ICIs

- There are currently no predictive biomarkers for response to ICI in ES-SCLC which have been validated for use in clinical practice¹
- The clinical utility of PD-L1 expression and TMB is still under investigation¹

PD-L1

 In both CASPIAN and IMPower-133, response to ICIs was independent of PD-L1 expression^{2,3}

TMB

 In both CASPIAN and IMPower-133, TMB was not predictive of treatment outcomes^{3,4}

ES-SCLC, small cell lung cancer; ICI, immune checkpoint inhibitor; PD-L1, programmed death-ligand 1; ES-SCLC, small cell lung cancer; TMB, tumour mutational burden. 1. Ortega-Franco A, et al. *ESMO Open*. 2021;6:100003; 2. Paz-Ares L, et al. *Ann Oncol*. 2019;30(Suppl. 5):v928–9; 3. Liu SV, et al. *J Clin Oncol*. 2021;39:619–30; 4. Goldman JW, et al. *Ann Oncol*. 2020;31(Suppl. 4):S1212–3



2019: Rudin et al proposed a consensus nomenclature for the molecular subtypes of SCLC¹



2021: Gay et al proposed a revised classification, replacing SCLC-Y with SCLC-I²

SCLC-A	SCLC-N	SCLC-I	SCLC-P
ASCL1	NeuroD1	Inflamed gene signature and low levels of ASCL1, NeuroD1 and POU2F3	POU2F3



SCLC, small cell lung cancer. 1. Rudin CM, et al. *Nat Rev Cancer*. 2019;19:289–97; 2. Gay CM, et al. *Cancer Cell*. 2021;39:346–60.e7.